Sanofi’s next-generation rheumatoid arthritis drug Kevzara has been approved in Europe, giving a new option for patients who are intolerant to other treatments.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
